Leading the Way in Life Science Technologies

GEN Exclusives

More »

Reprints And Permissions

Genetic Engineering & Biotechnology News (GEN) is pleased to announce our partnership with Copyright Clearance Center to meet your licensing needs.

With Copyright Clearance Center's Rightslink® service it's faster and easier than ever before to secure permission from GEN to reuse our content in a book, journal/magazine, newsletter/newspaper, CD-ROM/DVD, brochure/pamphlet, photocopy, coursepack, email, slide kit/presentation or order reprints.

Simply locate your desired content on http://www.genengnews.com/, click the Reprints link in the Keywords and Tools section to open Rightslink.

  1. Select the way you would like to reuse the content
  2. Create an account if you haven't already
  3. Accept the terms and conditions and you're done

For questions about using the Rightslink service, please contact Customer Support via phone 877/622-5543 (toll free) or 978/777-9929, or email [email protected].

If you prefer, please contact us directly:
Reprints & Permissions
Mary Ann Liebert, Inc., publishers
(914) 740-2100 or (800) M-LIEBERT
[email protected]

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »